Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Investment analysts at Jefferies Financial Group upped their Q4 2019 earnings per share estimates for shares of Alexion Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 15th. Jefferies Financial Group analyst E. Yang now expects that the biopharmaceutical company will post earnings of $2.58 per share for the quarter, up from their prior forecast of $2.26. Jefferies Financial Group also issued estimates for Alexion Pharmaceuticals’ Q1 2020 earnings at $2.59 EPS and FY2020 earnings at $10.13 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the company posted $2.02 EPS. The company’s revenue was up 23.0% compared to the same quarter last year.
ALXN has been the topic of a number of other research reports. Morgan Stanley upped their target price on shares of Alexion Pharmaceuticals from $128.00 to $131.00 and gave the company an “equal weight” rating in a research report on Friday. Bank of America began coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, October 17th. They issued a “buy” rating on the stock. William Blair reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 14th. SunTrust Banks began coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, November 12th. They issued a “buy” rating and a $125.00 target price on the stock. Finally, ValuEngine raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $154.00.
NASDAQ ALXN opened at $113.27 on Friday. The firm’s 50-day moving average is $110.45 and its two-hundred day moving average is $110.05. Alexion Pharmaceuticals has a 12 month low of $94.59 and a 12 month high of $141.86. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. The stock has a market capitalization of $24.90 billion, a P/E ratio of 12.30, a PEG ratio of 0.78 and a beta of 1.64.
Institutional investors and hedge funds have recently modified their holdings of the company. New York State Teachers Retirement System lifted its position in shares of Alexion Pharmaceuticals by 0.4% during the third quarter. New York State Teachers Retirement System now owns 311,593 shares of the biopharmaceutical company’s stock worth $30,517,000 after purchasing an additional 1,199 shares in the last quarter. UBS Group AG lifted its position in shares of Alexion Pharmaceuticals by 7.3% during the second quarter. UBS Group AG now owns 254,181 shares of the biopharmaceutical company’s stock worth $33,293,000 after purchasing an additional 17,371 shares in the last quarter. Altman Advisors Inc. lifted its position in shares of Alexion Pharmaceuticals by 13.6% during the third quarter. Altman Advisors Inc. now owns 15,627 shares of the biopharmaceutical company’s stock worth $1,531,000 after purchasing an additional 1,873 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Alexion Pharmaceuticals by 148.6% during the third quarter. SG Americas Securities LLC now owns 49,669 shares of the biopharmaceutical company’s stock worth $4,865,000 after purchasing an additional 29,691 shares in the last quarter. Finally, Man Group plc lifted its position in shares of Alexion Pharmaceuticals by 347.3% during the third quarter. Man Group plc now owns 513,104 shares of the biopharmaceutical company’s stock worth $50,254,000 after purchasing an additional 398,394 shares in the last quarter. 91.53% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.